Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bausch Health Companies (BHC – Research Report), PTC Therapeutics (PTCT – Research Report) and Akili (AKLI – Research Report).
Bausch Health Companies (BHC)
Bank of America Securities analyst Jason Gerberry maintained a Sell rating on Bausch Health Companies yesterday and set a price target of $6.00. The company’s shares closed last Wednesday at $7.47.
According to TipRanks.com, Gerberry is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Bausch Health Companies with a $8.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
PTC Therapeutics (PTCT)
Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on PTC Therapeutics yesterday and set a price target of $43.00. The company’s shares closed last Wednesday at $58.29, close to its 52-week high of $58.58.
According to TipRanks.com, Ahmad is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for PTC Therapeutics with a $53.46 average price target, implying a -3.1% downside from current levels. In a report released yesterday, Goldman Sachs also maintained a Sell rating on the stock with a $37.00 price target.
Akili (AKLI)
In a report released yesterday, Michael Cherny from Bank of America Securities reiterated a Hold rating on Akili, with a price target of $1.75. The company’s shares closed last Wednesday at $1.40, close to its 52-week low of $0.86.
According to TipRanks.com, Cherny is a 4-star analyst with an average return of
Akili has an analyst consensus of Moderate Buy, with a price target consensus of $3.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BHC:
- Bausch Health Soars on Trial Win
- Bausch Health Companies (BHC) Q1 Earnings Cheat Sheet
- Ortho Dermatologics announces FDA acceptance of NDA filing for IDP-126 Gel
- Bausch Health call volume above normal and directionally bullish
- Salix partners with Colorectal Cancer Alliance on community screening program
